Biohit Oyj - Decisions of general meeting

Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Stock Exchange Release April 25, 2016 at 5:15 pm local time (EEST)


The Annual General Meeting (AGM) of Biohit Oyj held on Monday April 25, 2016
approved the financial statements of the parent company and the consolidated
financial statements, and discharged the members of the Board of Directors and
the President and CEO from liability for the financial year 2015. 

Distribution of dividends

The AGM approved the Board of Directors proposal that no dividend shall be paid
for the financial period ended on December 31, 2015. 

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be
six (6) and elected the following Board members until the end of the next AGM: 
current members Professor Osmo Suovaniemi, Professor Mikko Salaspuro,
Commercial Counselor Eero Lehti, M. Sc. Eng. Seppo Luode, Managing Director
Franco Aiolfi and Master of Political Science Janina Andersson. 

Additionally, the AGM decided that the Chairman of the Board of Directors would
be paid a meeting fee of EUR 1,600 and the other Board members would be paid a
meeting fee of EUR 1,500. 

Election and remuneration of the Auditor

The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the
company’s auditor until the end of the next AGM. The auditor will be paid
remuneration against the auditor’s invoice. 

 Authorization of the Board of Directors to decide on the issue of shares and
to issue special rights entitling the receipt of shares 

The AGM decided to authorise the Board to decide on the issue of shares and to
issue special rights referred to in Chapter 10, section 1 of the Limited
Liability Companies Act entitling the receipt of shares with the following
terms and conditions: 

 The maximum number of new Series B shares to be issued pursuant to the special
rights is 3,000,000, which corresponds to approximately 26.4% of the company’s
all existing Series B shares. 

 The authorisation includes the Board of Directors’ entitlement to decide on
all terms and conditions regarding the issue of special rights. The issue of
shares and the issue of special rights entitling to the receipt of shares can
occur deviant from the subscription right of the shareholders (special issue).
The authorization remains valid for two years from the resolution of the GM and
the authorisation replaces the former authorisations. 

All decisions of the AGM were made unanimously. The minutes of the AGM will be
available for review by shareholders by May 2, 2016 on the company’s website
(www.biohithealthcare.com /investors) and at the corporate headquarters of
Biohit, located at Laippatie 1, 00880 Helsinki. 


Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com